What do systematic reviews say?

Allopurinol vs benzbromarone

The review found no eligible studies for this question.

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Allopurinol vs placebo

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 51 participants
  GRADE not reported

Allopurinol vs placebo

The review found no eligible studies for this question.

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Allopurinol vs placebo

The review found no eligible studies for this question.

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Allopurinol vs placebo

Allopurinol showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  RR 1.36 [0.61, 3.08]
  2 studies · 453 participants
  Moderate

Allopurinol vs placebo

Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
  RR 1.93 [0.48, 7.8]
  2 studies · 453 participants
  Moderate

Keratinocyte GF 50 mg vs Keratinocyte GF 25 mg

Keratinocyte GF 50 mg showed no clear difference in oral mucositis (moderate to severe) compared with keratinocyte GF 25 mg; GRADE not reported.

• Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes

  Median 28 days
  RR 0.78 [0.4, 1.49]
  1 study · 28 participants
  GRADE not reported

Keratinocyte GF 50 mg vs Keratinocyte GF 25 mg

Keratinocyte GF 50 mg showed no clear difference in oral mucositis (severe) compared with keratinocyte GF 25 mg; GRADE not reported.

• Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes

  Median 28 days
  RR 0.33 [0.04, 2.83]
  1 study · 28 participants
  GRADE not reported

Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)

It is very uncertain whether myo‐inositol changes live birth compared with placebo, no/standard treatment (very low certainty).

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  OR 2.42 [0.75, 7.83]
  2 studies · 84 participants
  Very low

Myo‐inositol vs antioxidant (melatonin)

The review found no eligible studies for this question.

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Myo‐inositol vs metformin

The review found no eligible studies for this question.

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Myo‐inositol vs metformin

The review found no eligible studies for this question.

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Myo‐inositol vs metformin

It is very uncertain whether myo‐inositol changes clinical pregnancy compared with an insulin‐sensitising agent (metformin) (very low certainty).

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  OR 1.91 [0.81, 4.49]
  1 study · 120 participants
  Very low

Myo‐inositol vs metformin

It is very uncertain whether myo‐inositol changes ovulation compared with an insulin‐sensitising agent (metformin) (very low certainty).

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  OR 1.86 [0.89, 3.87]
  1 study · 120 participants
  Very low

Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)

It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with placebo, no/standard treatment (very low certainty).

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  OR 0.4 [0.19, 0.86]
  4 studies · 535 participants
  Very low

Myo‐inositol vs clomiphene

It is very uncertain whether myo‐inositol changes live birth compared with an ovulation induction agent (clomiphene) (very low certainty).

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  OR 1.27 [0.48, 3.4]
  1 study · 75 participants
  Very low

Myo‐inositol vs clomiphene

The review found no eligible studies for this question.

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Myo‐inositol vs clomiphene

It is very uncertain whether myo‐inositol changes adverse event ‐ multiple pregnancy compared with an ovulation induction agent (clomiphene) (very low certainty).

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  OR 0.21 [0.01, 4.43]
  1 study · 75 participants
  Very low

Myo‐inositol vs clomiphene

The review found no eligible studies for this question.

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Myo‐inositol vs clomiphene

It is very uncertain whether myo‐inositol changes ovulation rate compared with an ovulation induction agent (clomiphene) (very low certainty).

• Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
  OR 0.59 [0.2, 1.68]
  1 study · 75 participants
  Very low